Form 4: Esperion Therapeutics Executive Sells Shares to Cover Tax Obligations

Esperion Therapeutics' Chief Commercial Officer, Eric Warren, sold 197 shares of common stock to cover tax obligations related to vested restricted stock units.

Summary

• Eric Warren, Chief Commercial Officer of Esperion Therapeutics, sold 197 shares of common stock on November 19, 2024.
• The shares were sold at a price of $2.165 per share.
• This transaction was to satisfy tax obligations arising from the vesting of restricted stock units.
• Following the sale, Warren directly owns 162,355 shares of Esperion Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, with no indication of positive or negative sentiment towards the company's prospects.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across publicly traded companies.
• The number of shares sold is relatively small compared to the total holdings of the executive, suggesting this is a routine tax-related transaction rather than a significant change in sentiment.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a small sale by an executive for tax purposes.

Key Dates

Keywords

Esperion Therapeutics, Eric Warren, stock sale, Form 4, insider trading, Chief Commercial Officer, tax obligations, restricted stock units